Adenosine as a neuromodulator in neurological diseases

Current Opinion in Pharmacology

Volumn 8, Issue 1, 2008, Pages 2-7

  Boison, Detlev ^a  

^a LEGACY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE KINASE INHIBITOR; ISTRADEFYLLINE;

BRAIN FUNCTION; BRAIN ISCHEMIA; CELL THERAPY; CHRONIC PAIN; CLINICAL TRIAL; EPILEPSY; EPILEPTOGENESIS; HUMAN; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEIZURE;

ADENOSINE; ADENOSINE KINASE; ALZHEIMER DISEASE; ANIMALS; BRAIN DISEASES; BRAIN ISCHEMIA; EPILEPSY; HUMANS; HUNTINGTON DISEASE; PAIN; PARKINSON DISEASE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 38649097860     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.09.002     Document Type: Review

References (50)

1. Fredholm B.B., Chen J.F., Cunha R.A., Svenningsson P., and Vaugeois J.M. Adenosine and brain function. Int Rev Neurobiol 63 (2005) 191-270
2. Jacobson K.A., and Gao Z.G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5 (2006) 247-264
3. Cunha-Reis D., Fontinha B.M., Ribeiro J.A., and Sebastiao A.M. Tonic adenosine A1 and A2A receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus. Neuropharmacol 52 (2007) 313-320
4. Boison D. Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. Neurodegener Dis 4 (2007) 28-33
5. Cunha R.A. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal 1 (2005) 111-134
6. Yin H.H., and Knowlton B.J. The role of the basal ganglia in habit formation. Nat Rev Neurosci 7 (2006) 464-476
7. Silva C.G., Porciuncula L.O., Canas P.M., Oliveira C.R., and Cunha R.A. Blockade of adenosine A(2A) receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol Dis (2007)
8. Ciruela F., Casado V., Rodrigues R.J., Lujan R., Burgueno J., Canals M., Borycz J., Rebola N., Goldberg S.R., Mallol J., et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26 (2006) 2080-2087
9. Fuxe K., Ferre S., Genedani S., Franco R., and Agnati L.F. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav (2007)
10. Martin E.D., Fernandez M., Perea G., Pascual O., Haydon P.G., Araque A., and Cena V. Adenosine released by astrocytes contributes to hypoxia-induced modulation of synaptic transmission. Glia 55 (2007) 36-45
11. Halassa M.M., Fellin T., Takano H., Dong J.H., and Haydon P.G. Synaptic islands defined by the territory of a single astrocyte. J Neurosci 27 (2007) 6473-6477
12. Halassa M.M., Fellin T., and Haydon P.G. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13 (2007) 54-63
13. Studer F.E., Fedele D.E., Marowsky A., Schwerdel C., Wernli K., Vogt K., Fritschy J.-M., and Boison D. Shift of adenosine kinase expression from neurons to astrocytes during postnatal development suggests dual functionality of the enzyme. Neuroscience 142 (2006) 125-137
14. Haydon P.G., and Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 86 (2006) 1009-1031
15. Pascual O., Casper K.B., Kubera C., Zhang J., Revilla-Sanchez R., Sul J.Y., Takano H., Moss S.J., McCarthy K., and Haydon P.G. Astrocytic purinergic signaling coordinates synaptic networks. Science 310 (2005) 113-116. By generating inducible transgenic mice that express a dominant-negative SNARE domain selectively in astrocytes, the vesicular release of neurotransmitters was selectively blocked in astrocytes. Using these animals it was demonstrated for the first time that adenosine-mediated tonic suppression of synaptic transmission was dependent on astrocytic vesicular release of ATP. These studies demonstrated that astrocytes are crucially involved in regulating and fine-tuning synaptic strength and plasticity.
16. Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci 27 (2006) 652-658
17. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 11 (2005) 25-36
18. 1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 200 (2006) 184-190
19. Kochanek P.M., Vagni V.A., Janesko K.L., Washington C.B., Crumrine P.K., Garman R.H., Jenkins L.W., Clark R.S., Homanics G.E., Dixon C.E., et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 26 (2006) 565-575
20. Dare E., Schulte G., Karovic O., Hammarberg C., and Fredholm B.B. Modulation of glial cell functions by adenosine receptors. Physiol Behav (2007)
21. Abdelmalik P.A., Shannon P., Yiu A., Liang P., Adamchik Y., Weisspapir M., Samoilova M., Burnham W.M., and Carlen P.L. Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction. Neurobiol Dis 26 (2007) 646-660
22. Fedele D.E., Gouder N., Güttinger M., Gabernet L., Scheurer L., Rulicke T., Crestani F., and Boison D. Astrogliosis in epilepsy leads to overexpression of adenosine kinase resulting in seizure aggravation. Brain 128 (2005) 2383-2395. This is a demonstration that transgenic overexpression of adenosine kinase in brain alters seizure susceptibility. Upregulated ADK was associated with a reduced tone of the endogenous anticonvulsant adenosine and with spontaneous seizures and lowered seizure thresholds.
23. Li T., Steinbeck J.A., Lusardi T., Koch P., Lan J.Q., Wilz A., Segschneider M., Simon R.P., Brustle O., and Boison D. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 130 (2007) 1276-1288. Embryonic stem cells engineered to release adenosine by biallelic disruption of the adenosine kinase gene were differentiated into neural precursor cells and transplanted into the infrahippocampal cleft of rats before the onset of kindling. Animals with adenosine releasing intrahippocampal implants were characterized with a significant suppression of kindling development. This is the first study to demonstrate an antiepileptogenic potential of adenosine.
24. Boison D. Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol 5 (2007) 115-125
25. Frenguelli B.G., Wigmore G., Llaudet E., and Dale N. Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. J Neurochem 101 (2007) 1400-1413
26. Pearson T., Damian K., Lynas R.E., and Frenguelli B.G. Sustained elevation of extracellular adenosine and activation of A(1) receptors underlie the post-ischemic inhibition of neuronal function in rat hippocampus in vitro. J Neurochem 97 (2006) 1357-1368. This study combined electrophysiology with synchronized online detection of adenosine using microelectrode biosensors for adenosine. Using this ingenious approach, the authors convincingly demonstrate a link between the post-ischemic rise in adenosine and inhibition of neurotransmission.
27. Gidday J.M. Cerebral preconditioning and ischemic tolerance. Nat Rev Neurosci 7 (2006) 437-448
28. Stenzel-Poore M.P., Stevens S.L., King J.S., and Simon R.P. Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke 38 (2007) 680-685
29. Trendelenburg G., and Dirnagl U. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia 50 (2005) 307-320
30. Pignataro G., Maysami S., Studer F.E., Wilz A., Simon R.P., and Boison D. Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. J Cereb Blood Flow Metab 28 (2008) 17-23
31. Pignataro G., Simon R.P., and Boison D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab 27 (2007) 1-5
32. Pignataro G., Studer F.E., Wilz A., Simon R.P., and Boison D. Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants. J Cereb Blood Flow Metab 27 (2007) 919-927
33. Sawynok J. Adenosine and ATP receptors. Handb Exp Pharmacol (2007) 309-328
34. McGaraughty S., and Jarvis M.F. Purinergic control of neuropathic pain. Drug Dev Res 67 (2006) 376-388
35. Ferre S., Diamond I., Goldberg S.R., Yao L., Hourani S.M., Huang Z.L., Urade Y., and Kitchen I. Adenosine A(2A) receptors in ventral striatum, hypothalamus and nociceptive circuitry: Implications for drug addiction, sleep and pain. Prog Neurobiol (2007)
36. Godfrey L., Yan L., Clarke G.D., Ledent C., Kitchen I., and Hourani S.M. Modulation of paracetamol antinociception by caffeine and by selective adenosine A2 receptor antagonists in mice. Eur J Pharmacol 531 (2006) 80-86
37. Hussey M.J., Clarke G.D., Ledent C., Hourani S.M., and Kitchen I. Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A2A receptor knockout mice. Pain 129 (2007) 287-294
38. 2AR antagonists.
39. Schiffmann S.N., Fisone G., Moresco R., Cunha R.A., and Ferre S. Adenosine A(2A) receptors and basal ganglia physiology. Prog Neurobiol 83 (2007) 277-292
40. Fuxe K., Marcellino D., Genedani S., and Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov Disord 22 (2007) 1990-2017
41. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., Shippy D., and Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neurosci 142 (2006) 941-952
42. Dall'Igna O.P., Fett P., Gomes M.W., Souza D.O., Cunha R.A., and Lara D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 203 (2007) 241-245
43. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., and Abbracchio M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol 81 (2007) 331-348
44. Maglione V., Cannella M., Martino T., De Blasi A., Frati L., and Squitieri F. The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neurosci Lett 393 (2006) 27-30
45. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., and Abbracchio M.P. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis 23 (2006) 44-53
46. 2ARs, is uniquely positioned to influence glutamatergic and dopaminergic neurotransmission.
47. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 10 (2006) 515-531
48. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., et al. Psychosis pathways converge via D2 high dopamine receptors. Synapse 60 (2006) 319-346
49. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., and Coyle J.T. Neurobiology of schizophrenia. Neuron 52 (2006) 139-153
50. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., Knuesel I., Benke D., Feldon J., Mohler H., et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a pro-cognitive and anti-psychotic phenotypic profile. J Neurosci 26 (2006) 3169-3181